1. Antiarrhythmic Properties of Non-Antiarrhythmic Drugs in Atrial Fibrillation: Upstream Therapy
   Alina Scridon et al, 2020, Antiarrhythmic Drugs CrossRef
2. Артериалдык гипертонияны дарылоо. Бир таблеткада амлодипин/валсартан менен айкалыштырылган дарылоого көңүл буруңуз
   Э.М. Миррахимов, 2024, Scientific and practical journal Healthcare of Kyrgyzstan CrossRef
3. The Role of the Rho/ROCK Pathway in Ang II and TGF-β1-Induced Atrial Remodeling
   Li-Juan Liu et al, 2016, PLOS ONE CrossRef
4. The Effect of Renin-Angiotensin System Inhibitors on the Recurrence of Atrial Fibrillation After Catheter Ablation
   Jianqiang Zhao et al, 2020, International Heart Journal CrossRef
5. A Systematic Review and Meta-analysis of Renin–angiotensin System Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence After Atrial Fibrillation Ablation
   Qian Sun et al, 2024, Journal of Cardiovascular Pharmacology CrossRef
6. Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial
   Zhiqiang Zhao et al, 2020, Clinical Cardiology CrossRef
7. Predictors of outcome after catheter ablation for atrial fibrillation: Group analysis categorized by age and type of atrial fibrillation
   Tetsuya Uemura et al, 2023, Annals of Noninvasive Electrocardiology CrossRef
8. Renin-Angiotensin System Inhibitors for the Prevention of Atrial Fibrillation Recurrence After Ablation ― A Meta-Analysis ―
   Long Peng et al, 2020, Circulation Journal CrossRef
9. Redefining the Blanking Period After Catheter Ablation for Paroxysmal Atrial Fibrillation
   Stephan Willems et al, 2016, Circulation: Arrhythmia and Electrophysiology CrossRef